Author

Lanni Aquila

Institution: Frontier Science & Technology Research Foundation, Inc.

Observed institutions: Roswell Park Comprehensive Cancer Center, Frontier Science & Technology Research Foundation, Inc., Canisius College

ORCID: 0000-0001-5648-5877

Observed ORCID: 0000-0001-5648-5877

OpenAlex ID: A5022799038

Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer

2019 · Swathi Ramakrishnan, Victoria Granger, et al. · Cell Death and Differentiation · 91

Regulation of Histone Ubiquitination in Response to DNA Double Strand Breaks

2020 · Lanni Aquila, Boyko S. Atanassov · Cells · 36

The role of STAG2 in bladder cancer

2018 · Lanni Aquila, Joyce Ohm, et al. · Pharmacological Research · 23

Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet)

2026 · Ajay Bansal, Elena M. Stoffel, et al. · Frontiers in Immunology

Abstract A22: STAG2, a novel genetic regulator of bladder cancer

2020 · Nithya Krishnan, Lanni Aquila, et al. · Clinical Cancer Research

Corrigendum to “The role of STAG2 in bladder cancer” [Pharmacol. Res. 131 (2018) 143–149]

2019 · Lanni Aquila, Joyce Ohm, et al. · Pharmacological Research

Abstract 1389: Effects of geinstein on histone modifying enzyme expression in prostate cancer

2017 · Lanni Aquila, Nick Smothermon, et al. · Cancer Research

Works count: 7

Citation count: 150

H-index: 3

I10-index: 3